STAT+ reports that China is tightening oversight of clinical trials, even as U.S. stakeholders seek ways to match China’s historically faster pace. A key focus is on investigator-initiated trials (ITTs), which previously allowed researchers to start trials without National Medical Products Administration (NMPA) sign-off and without the higher bar of mandatory review. The piece says the ITT model helped accelerate translation, broaden physician involvement, and support rapid commercialization after approvals. It also notes mounting scrutiny tied to patient-safety concerns, weaker transparency, and questions around how intellectual property was handled. For biotech, the near-term impact is operational: sponsors and contract research partners may need to revisit trial start timelines, compliance workflows, and documentation expectations for China programs that previously leaned on ITT flexibility.